| Autor: |
Das I; Pt. J.N.M. Medical College, Raipur, India., Mishra H; Sickle Cell Institute Chhattisgarh, Raipur, India., Khodiar PK; Pt. J.N.M. Medical College, Raipur, India., Patra PK; Pt. J.N.M. Medical College, Raipur, India. |
| Jazyk: |
angličtina |
| Zdroj: |
Bioinformation [Bioinformation] 2018 Jul 31; Vol. 14 (7), pp. 408-413. Date of Electronic Publication: 2018 Jul 31 (Print Publication: 2018). |
| DOI: |
10.6026/97320630014408 |
| Abstrakt: |
Sickle cell disease (SCD) is life-threatening hemoglobinopathy prevalent in India, Sub-Saharan Africa and Middle East. Inflammation plays a pivotal role in disease process and involves intricate interaction among leukocytes, platelets, sickle erythrocytes and vascular endothelium. Available disease modifying therapies are hydroxyl-urea and blood transfusion. Therefore, it is of interest to develop improved pharmacological agents for SCD. We report up-regulated genes in steady state and vaso-occlusive crisis using analysis of gene expression data obtained by microarray experiment for SCD as potential targets. The association of these targets with inflammation in pathway analysis is also documented. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
